ULK1/2 Inhibitors that Degrade ATG13 Effectively Target KRAS-Mutant Cancers
Authors:
- Patrick M. HaganPHPatrick M. Hagan
- Huiyu RenHRHuiyu Ren
- Sonja N. BrunSBSonja N. Brun
- Fabiana I. A. LayngFLFabiana I. A. Layng
- Dhanya R. PanickarDPDhanya R. Panickar
- Lester J. LambertLLLester J. Lambert
- Maria CeleridadMCMaria Celeridad
- Ranajit DasRDRanajit Das
- Li LingLLLi Ling
- Yijuan ZhangYZYijuan Zhang
- Allison S. LimpertALAllison S. Limpert
- Douglas J. ShefflerDSDouglas J. Sheffler
Preprint
Abstract
KRAS mutations drive tumorigenesis in multiple cancer types, including lung and pancreatic cancer. Autophagy is a cell survival pathway that supports tumor growth under metabolic stress and has been proposed to be a potential therapeutic avenue specifically in KRAS mutant cancers. The Unc-51-like ATG-activating kinases 1 and 2 (ULK) initiate the earliest regulated steps of autophagy and are the only protein kinases in the canonical autophagy pathway, thus making them attractive therapeutic targets for KRAS mutant tumors. We show here that genetic depletion of ULK1 or ATG13, core components of the ULK1 complex, in KRAS mutant lung and pancreatic cancer cell lines results in growth inhibition. Previously, we developed small molecule ULK1 inhibitors that not only inhibit ULK kinase activity but also induced the degradation of other core members of the ULK complex including ATG101 and ATG13. Therefore, we developed a high-throughput screening (HTS) assay in which ATG13 was HiBiT-tagged in KRAS mutant lung cancer cells to evaluate ULK inhibitors for ATG13 degradation. Using this approach, we discovered a lead ULK inhibitor, SBP-1750 , that potently inhibited ULK activity, promoted robust ATG13 degradation, impaired ATG, and induced KRAS mutant cancer cell death. Studies in a KRAS-mutant orthotopic syngeneic pancreatic cancer model show that oral treatment with SBP-1750 significantly reduced tumor growth. Pharmacokinetic analysis of SBP-1750 indicates favorable drug exposure and pharmacodynamic analysis confirms ATG13 degradation in vivo, mirroring in vitro results. Finally, immunohistochemical staining of orthotopic pancreatic tumors reveals a significant increase in CD4⁺ and CD8⁺ T cell infiltration upon treatment, suggesting that SBP-1750 enhances anti-tumor immunity. These findings support further development of SBP-1750 as a novel ATG-targeting cancer therapy.Keywords
Funding Information
- Epstein Family Foundation
- Curebound (2022 Discovery Grant)
- Curebound (2023 Discovery Grant 23TG05)
- National Cancer Institute (P30CA030199)
- National Cancer Institute (R35CA220538)
- National Cancer Institute (P01CA120964)
- National Cancer Institute (F32CA206400)
This publication has 47 references indexed in Scilit:
- Molecular glues and PROTACs in targeted protein degradation: mechanisms, advances, and therapeutic potentialBiochemical Pharmacology, 2025
- Macropinocytosis maintains CAF subtype identity under metabolic stress in pancreatic cancerCancer Cell, 2025
- Molecular glues for protein-protein interactions: Progressing toward a new dreamCell Chemical Biology, 2024
- Autophagy in cancer immunotherapy: Perspective on immune evasion and cell death interactionsCancer Letters, 2024
- Targeted protein degradation: Emerging concepts and protein state-specific targeting principlesCurrent Opinion in Chemical Biology, 2022
- Autophagy and Ubiquitin-Proteasome System2019
- CD4 and CD8 T lymphocyte interplay in controlling tumor growthCellular and Molecular Life Sciences, 2017
- Autophagy-Independent Lysosomal Targeting Regulated by ULK1/2-FIP200 and ATG9Cell Reports, 2017
- The role of the Atg1/ULK1 complex in autophagy regulationCurrent Opinion in Cell Biology, 2010
- Autophagy in the Pathogenesis of DiseaseCell, 2008